Related Experiment Video

Updated: Jul 9, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.2K

[Castleman's disease, pathophysiology, advances in diagnosis and treatment]

Roberto Pertusa Mataix1, Daniel Loaiza Cabello1, José Salvador García Morillo1

  • 1Servicio de Medicina Interna, Departamento de Enfermedades Autoinmunes, Hospital Universitario Virgen del Rocío, Sevilla, España.

Medicina Clinica
|November 28, 2023
PubMed

Insights

Castleman's disease (CD) is a rare lymphoproliferative disorder with unknown incidence, affecting two age groups. Treatment includes anti-interleukin-6 (IL-6) therapies like siltuximab.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Castleman's disease (CD) is a rare lymphoproliferative disorder with distinct histological features.
  • CD exhibits a bimodal age distribution (30-40 and 60-80 years) and is classified into hyalinovascular and plasmocellular subtypes.
  • The plasmocellular form is associated with HIV and HHV-8, leading to interleukin-6 (IL-6) overproduction.

Purpose of the Study:

  • To provide a comprehensive overview of Castleman's disease.
  • To discuss the classification, pathogenesis, and epidemiological characteristics of CD.
  • To highlight current and emerging treatment strategies for CD.

Main Methods:

  • Literature review of Castleman's disease.
  • Analysis of epidemiological data and disease classification.
  • Review of therapeutic approaches, including targeted therapies.

Main Results:

  • Castleman's disease is a rare condition with an estimated incidence below 1 in 100,000.
  • The unicentric variant shows a slight female predominance (2:1 ratio).
  • Interleukin-6 (IL-6) plays a crucial role in CD pathogenesis, particularly in the plasmocellular form.

Conclusions:

  • Castleman's disease requires further epidemiological study and understanding of its pathogenesis.
  • Targeted therapies, such as anti-IL-6 agents like siltuximab, represent a significant advancement in CD treatment.
  • Siltuximab is an approved orphan drug for Castleman's disease, offering a promising therapeutic option.

Keywords:
CastlemanInterleucina 6Interleukin-6Siltuximab

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

464
Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.4K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
172
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
252